| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aridis Pharmaceuticals, Inc. | Director | Stock options | 261,000 | 27 Jun 2024 | Direct | ||
| Humacyte, Inc. | Director | Stock Options (right to buy) | 80,000 | 12 Jun 2025 | Direct | ||
| Humacyte, Inc. | Director | Stock Options (right to buy) | 50,000 | 13 Jun 2024 | Direct | ||
| Histogen Inc. | Director | Stock Option (right to buy) | 6,835 | 20 Jun 2023 | Direct |